



BML517346

Laboratory Investigation Report

Name	: Mr. NATALY ESPERANZA MANTILLA VELASQUEZ	Ref No.	: 45643
DOB	: 29/09/1989	Sample No.	: 2501529983
Age / Gender	: 35 Y / Male	Collected	: 25/01/2025 15:32
Referred by	: Dr. AMAIZAH	Registered	: 25/01/2025 22:34
Centre	: CITICARE MEDICAL CENTER	Reported	: 26/01/2025 10:33

BIOCHEMISTRY

Test	Result	Flag	Unit	Reference Range	Methodology
C-REACTIVE PROTEIN (CRP)	8.1	H	mg/L	< 5.0 Please note change. Source: Roche IFU.	Particle-enhanced immunoturbidimetric assay

INTERPRETATION NOTES :

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection.

Sample Type : Serum

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Vyoma V. Shah
Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

Haleem
HALEEM HAKKIM
Laboratory Technician


This is an electronically authenticated report

Page 1 of 3

Printed on: 26/01/2025 11:45

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





BML517346

Laboratory Investigation Report

Name : Mr. NATALY ESPERANZA MANTILLA VELASQUEZ
DOB : 29/09/1989
Age / Gender : 35 Y / Male
Referred by : Dr. AMAIZAH
Centre : CITICARE MEDICAL CENTER

Ref No. : 45643
Sample No. : 2501529983
Collected : 25/01/2025 15:32
Registered : 25/01/2025 22:34
Reported : 26/01/2025 11:43

HEMATOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
COMPLETE BLOOD COUNT (CBC)					
HEMOGLOBIN	13.6		g/dL	13.5 - 17.5	Photometric
RBC COUNT	4.5		10 ⁶ /μL	4.3 - 5.7	Electrical Impedance
HEMATOCRIT	39.9		%	38 - 50	Calculation
MCV	86.9		fL	82 - 98	Calculation
MCH	29.7		pg	27 - 32	Calculation
MCHC	34.1		g/dL	32 - 37	Calculation
RDW	13.0		%	11.8 - 15.6	Calculation
RDW-SD	39.4		fL		Calculation
MPV	10.0		fL	7.6 - 10.8	Calculation
PLATELET COUNT	292		10 ³ /uL	150 - 450	Electrical Impedance
PCT	0.2		%	0.01 - 9.99	Calculation
PDW	16.9		Not Applicable	0.1 - 99.9	Calculation
NUCLEATED RBC (NRBC)^	0.1		/100 WBC		VCS 360 Technology
ABSOLUTE NRBC COUNT^	0.01		10 ³ /uL		Calculation
EARLY GRANULOCYTE COUNT (EGC)^	0.3		%		VCS 360 Technology
ABSOLUTE EGC^	0.0		10 ³ /uL		Calculation
WBC COUNT	10.0		10 ³ /μL	4 - 11	Electrical Impedance
DIFFERENTIAL COUNT (DC)					
NEUTROPHILS	63		%	40 - 75	VCS 360 Technology
LYMPHOCYTES	27		%	20 - 45	VCS 360 Technology
EOSINOPHILS	3		%	0 - 6	VCS 360 Technology
MONOCYTES	6		%	1 - 6	VCS 360 Technology
BASOPHILS	1		%	0 - 1	VCS 360 Technology
ABSOLUTE COUNT					
ABSOLUTE NEUTROPHIL COUNT	6.3		10 ³ /uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	2.7		10 ³ /uL	0.8 - 4.95	Calculation
ABSOLUTE MONOCYTE COUNT	0.6		10 ³ /uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0.3		10 ³ /uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0.0		10 ³ /uL	0 - 0.11	Calculation

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Gyoma V. Shah
Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

Christeena
CHRISTEENA FRANCIS
Laboratory Technologist


This is an electronically authenticated report

Page 2 of 3

Printed on: 26/01/2025 11:45

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





Laboratory Investigation Report

Name	: Mr. NATALY ESPERANZA MANTILLA VELASQUEZ	Ref No.	: 45643
DOB	: 29/09/1989	Sample No.	: 2501529983
Age / Gender	: 35 Y / Male	Collected	: 25/01/2025 15:32
Referred by	: Dr. AMAIZAH	Registered	: 25/01/2025 22:34
Centre	: CITICARE MEDICAL CENTER	Reported	: 26/01/2025 11:43

HEMATOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
------	--------	------	------	-----------------	-------------

COMPLETE BLOOD COUNT (CBC)

INTERPRETATION NOTES :

Please note update on CBC report format, reference ranges and method(Beckman Coulter).

Sample Type : EDTA Whole Blood

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Vyoma V. Shah
Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

Christeena Francis
CHRISTEENA FRANCIS
Laboratory Technologist
Printed on: 26/01/2025 11:45

This is an electronically authenticated report

Page 3 of 3

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

